Abstract: A method of using a compound of the Formula (V) ##STR1## or a pharmaceutically acceptable salt thereof is disclosed, wherein R.sup.1 and R.sup.2 are each C.sub.1 to C.sub.6 aliphatic acyloxy, unsubstituted or substituted by halogen, or are each C.sub.7 to C.sub.

Abstract: The present invention relates to compounds of the formula I[CH.sub.3 --(CH.sub.2).sub.29 --O--].sub.m --R (I)whereinif m stands for 1, thenR represents a group derived from a mono- or di- or oligosaccharide by removing the hydrogen atom from the hydroxyl group being in the 1(alpha) or 1(beta) position, or the O-protected, preferably acetylated derivative thereof,if m stands for 2, thenR represents a group derived by removing a hydrogen atom attached to the carbon atom being in position 1 of the reaction product of glucose and mono-, di- or triethylene glycol or the O-protected, preferably O-acetylated derivative thereof.

Abstract: A pure crystalline O-(2-hydroxy-3-piperidino-1-propyl) nicotinic acid amidoxime base of the Formula (Ib) ##STR1## is disclosed characterized by a melting point of 70.degree. to 73.degree. C., giving, when dissolved in an amount of 1 to 10 ml of concentrated sulfuric acid, a yellow homogeneous solution, and showing the following spectral characteristics:IR spectrum (kBr): .gamma. --O--C.dbd.N 1642 cm.sup.-1.sup.1 H-NMR spectrum (CDCL.sub.3, .delta. ppm): 1.48 m, (6H), CH.sub.2 -piperidine; 2.42 m, (6H), 3.times.CH.sub.2 --N; 3.36, br, (1H), CH--O; 4.08 m, (3H), 1--CH.sub.2, OH; 5.2, br, (2H), NH.sub.2 ; 7.30 m (1H), pyridine-5'; 7.92 m, 4', 8.62 m (1H), 6', 8.88 m, (1H), 2'.

Abstract: A method for the selective determination of sialic acid-carrying glycolipid complexes in blood, in which the serum is diluted with water, then extracted with a water-immiscible organic solvent or solvent mixture to remove neutral lipids, a lipoprotein fraction containing sialic acid-carrying glycolipids is precipitated from the aqueous phase, the precipitated fraction is redissolved, and the sialic acid content of the solution or the amount and quality of the sialic acid-carrying glycolipid are determined by a method known per se. A water-soluble salt of a monovalent, bivalent or trivalent metal other than alkali metal is used as a precipitating agent in an amount corresponding to a final metal ion concentration of 0.005-0.1 mole/l in the mixture, and precipitation is performed at a pH of 1.5 to 8.0.

Abstract: The present invention relates to a process for the preparation of high purity crystalline peptides Arg Lys Asp hydrate acetate and Arg Lys Asp Val from crude, amorphous peptides Arg Lys Asp and Arg Lys Asp Val hydrate acetate.The process is characterized in thatthe crude, amorphous peptide Arg Lys Asp or Arg Lys Asp Val is let stand at room temperature in 5 to 20 unit volume of ethanol containing 0.5 to 4.0% by volume of acetic acid and 5 to 25% by volume of water, wherein the volume unit is calculated for the mass unit of the material and mass unit relates to volume unit as g relates to ml,then the crystallized peptide is separated from the crystalline suspension, preferably after cooling.

Abstract: The invention relates to a plant protecting or veterinary or additive composition, containing beside the active ingredient and other usually applied auxiliaries, such as solid and liquid carrier(s), surface active agent(s) and further additive(s), one or more surface active agent(s) of the general formulae (I) ##STR1## or a mixture thereof, wherein R, R.sup.2, R.sup.3 and R.sup.4 are independently from each other hydrogen atom, an organic or inorganic cation or a group of the general formula --(CH.sub.2 --CH.sub.2 --O).sub.n R.sup.1, whereinR.sup.1 is a C.sub.10-20 alkyl group andn is an integer from 4 to 20, with the provisio that from among the substituents R, R.sup.2 and R.sup.3 at least one is a group of the general formula (CH.sub.2 --CH.sub.2 O).sub.n R.sup.1.

Abstract: The gas to be treated contains H.sub.2 S and carbon compounds first enters the combustion chamber of a Claus process plant and a gas mixture which contains 1 to 3 moles H.sub.2 S per mole of SO.sub.2 is withdrawn from that combustion chamber. The gas mixture is reacted in part to form elemental sulfur in at least one catalytic Claus process stage at temperatures above the dew-point temperature of the sulfur. The elemental sulfur is condensed in and removed from a sulfur cooler. An exhaust gas which contains 0.5 to 5% by volume H.sub.2 S and also contains COS, CS.sub.2 and H.sub.2 O is withdrawn from the last sulfur cooler of the Claus process plant. Oxygen is admixed with that exhaust gas, which is heated to a temperature of at least 200.degree. C. and is contacted with a catalyst, which comprises at least 80% by weight TiO.sub.2. The resulting elemental sulfur is condensed and withdrawn. The gas is subsequently contacted at temperatures of 120.degree. to 160.degree. C.

Abstract: The invention relates to antibacterial pseudo-primycin complexes of formula (I) ##STR1## to the components and acid addition salts thereof, as well as to the preparation of these compounds and to the pharmaceutical compositions containing said compounds as active ingredient.In the formula (I) R.sup.1 is butyl, pentyl or hexyl, R.sup.2 is hydrogen, hydroxyl or O-arabinose and X is organic or inorganic acid ion.

Abstract: To a gas which contains H.sub.2 S and water vapor and which is to be desulfurized oxygen is added at such a rate that the gas contains 1 to 20 moles O.sub.2 per mole of H.sub.2 S. At a temperature in the range of 50.degree. to 180.degree. C. the gas is contacted with activated carbon, which is thus laden with elemental sulfur and with at least 3% by weight sulfuric acid. In a suitable processing, the gas which is to be desulfurized and contains at least 1000 ppm H.sub.2 S+SO.sub.2 is initially passed at a temperature from 100.degree. to 180.degree. C. through a catalytic prepurifier, in which elemental sulfur is adsorbed on a high-metal-oxide catalyst, oxygen is admixed to the gas coming from the prepurifier and the gas at a temperature of 50.degree. to 180.degree. is contacted with the activated carbon for a final desulfurization.

Abstract: The present invention relates to novel 4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide derivatives of the general formula (I) and the acid addition salts thereof, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I) ##STR1## R stands for a C.sub.1-12 alkyl group optionally substituted by a C.sub.1-4 alkoxycarbonyl group; a C.sub.3-9 cycloalkyl, adamantyl or optionally substituted phenyl group;R.sup.1 means hydrogen or a C.sub.1-4 alkyl group; orR and R.sup.1 together form a --(CH.sub.2).sub.n -- chain, wherein n is 4, 5 or 6;R.sup.2 stands for hydrogen, a C.sub.1-4 alkyl group or halogen;R.sup.3 represents hydrogen or a C.sub.1-4 alkyl group; andm is 0 or 1.The compounds of the general formula (I) possess a gastroprotective effect and are useful for the prevention and therapy of ulcers of the stomach and the small intestine.

Abstract: The present invention relates to novel pentapeptide of formulaXaa Glu Asp Ser Gly (SEQ ID NO: 1)wherein Xaa is pyro-alpha-aminoadipic acid, having specific inhibiting effect on epidermal cell proliferation, salts thereof, pharmaceutical compositions comprising the same and a method for the treatment of mammals for inhibiting the epidermal cell proliferation by administering the novel pentapeptide. The invention also covers a process for the preparation of both the pentapeptide and the pharmaceutical composition.

Abstract: In the reduction of liquid slags or molten salts which contain nonferrous metal oxides and are disposed over a liquid metal layer consisting of the corresponding nonferrous metal oxides and are disposed over a liquid metal layer consisting of the corresponding nonferrous metal, carbonaceous reducing agents and oxygen-containing gas are injected through nozzles into the metal layer. In order to improve the gasification of the reducing agent the height of the metal layer is so selected that at least 50% of the reducing agent are reacted to CO and optionally H.sub.2 in the metal layer before the reducing agent enters the slag layer.

Abstract: The invention relates to a process for the preparation of pure isoflavone derivatives of the general formula (I), ##STR1## wherein R stands for hydrogen or isopropyl,R.sup.2 and R.sup.3 stand for hydrogen or C.sub.1-2 alkoxy by reacting a rezorcinol-derivative of the general formula (III) ##STR2## wherein R.sup.2 and R.sup.3 are as given above with ethyl-orthoformiate of the formula (IV)(C.sub.2 H.sub.5 O).sub.3l CH (IV)in the presence of a base and optionally by alkylating the product.

Abstract: The invention relates to novel stable aqueous primycin solutions containing 0.5 to 1.75% by mass/volume of primycin sulfate or 2.5 to 9% by mass/volume of a complex of primycin N-methylpyrrolidone and 2 to 15% by mass/volume of pyroglutamic acid, preferably L-pyroglutamic acid or a soluble salt, preferably the sodium salt thereof as calculated for the volume of the solution to be prepared and 40 to 60% by volume of isopropanol as calculated for the volume of the solution to be prepared as well as water in an amount adding up to 100%. The stable, aqueous primycin solutions are topical antibiotics.

Abstract: The invention relates to a novel process for the preparation of 17 .alpha.-hydroxy-20-oxopregnane derivatives of the general formula (I), ##STR1## wherein R.sub.1 means a hydroxy or an oxo group; andthe dotted lines optionally represent one or more additional valence bond(s), with the proviso that the dotted line in the 4-position and the dotted line in the 5-position cannot each simultaneously be an additional valence bond from steroids having 23,24-dinor-17(20)-dehydrocholan-22-oic -22-oic acid structure.According to the process of the invention a steroid derivative having 23,24-dinorcholan-22-oic acid structure, containing a double bond in 17(20)-position, is transformed to 17.alpha., 20-epoxy-23,24-dinorcholanoic acid, the latter is converted to a reactive acid derivative, which is then reacted with a salt-containing azide ion to yield a 17.alpha., 20-epoxy-23,24-dinorcholanoic acyl azide derivative and the azide obtained is reacted with a mineral or organic acid in an aqueous medium.

Abstract: The invention relates to a method for protecting plants against stress or for increasing their yield, in which the plant is treated in its intense development stage or directly after flowering or before, during or maximum 5 days after the occurrence of stress with 0.001-10 kg/hectare of a compound of Formula (I), ##STR1## wherein X.sup.- is an agriculturally acceptable inorganic or organic anion. The invention also relates to a composition for protecting plants against stress or for increasing their yield, which comprises as active ingredient 0.001-95% by weight of a compound of formula (I).

Abstract: The invention relates to an improved, large scale process for the preparation of compounds of formula (I) ##STR1## wherein R is halogen atom or hydroxyl,R.sup.2 is hydrogen atom or hydroxyl,R.sup.3 and R.sup.4 are hydrogen or alkoxy having 1-6 carbon atoms.

Abstract: A process is disclosed for the preparation of (.+-.)-6-cyano-3,4-dihydro-2,2-dimethyl-trans-4-(2-oxo-1-pyrrol idino)-2H-1-benzopyran-3-ol of the Formula (VI) ##STR1## from 4-cyanophenol of the Formula (I) ##STR2## which comprises reacting 4-cyanophenol of the Formula (I) with isoprene, followed with bromination and dehydrobromination steps with formation of intermediates to react with 2-pyrrolidone resulting in obtaining the compound of the Formula (VI).

Abstract: The present invention relates to a pharmaceutical composition comprising as active ingredient a compound of the Formula I ##STR1## wherein R.sup.1 stands for straight or branched chain alkyl comprising 1 to 8 carbon atoms; phenyl alkyl having 7 to 10 carbon atoms; phenyl; or cycloalkyl comprising 3 to 8 carbon atoms;R.sup.2 stands for straight or branched chain alkyl comprising 1 to 8 carbon atoms; alkyl comprising 1 to 8 carbon atoms substituted by halogen, hydroxy, alkoxy having 1 to 4 carbon atoms or by one or two phenyl groups; phenyl; or cycloalkyl having 3 to 8 carbon atoms,with the proviso that groups R.sup.1 and R.sup.2 together contain at least three carbon atoms. The invention also relates to a process for the preparation of compounds of the Formula I by methods known per se.

Abstract: The invention relates to a stabile, aqueous suspoemulsion containing as active ingredient 0.2-5 weight % of primycin, 5-25 weight % of propylene glycol, 0.5-5 weight % of non-ionic surface active agent, if desired 15 weight % of auxiliary agent and distilled water in an amount necessary to 100 weight %, as well as to a process for the preparation thereof.